{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:28:09Z","timestamp":1782458889364,"version":"3.54.5"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40261-025-01505-z","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:17:18Z","timestamp":1762953438000},"page":"101-106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CT-P39: An Omalizumab Biosimilar"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5649-5651","authenticated-orcid":false,"given":"Michael B.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"1505_CR1","unstructured":"European Medicines Agency. Omlyclo: EU summary of product characteristics. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/omlyclo-epar-product-information_en.pdf. Accessed 29 Oct 2025."},{"key":"1505_CR2","unstructured":"Celltrion Inc. OMLYCLO\u00ae (omalizumab-igec) injection, for subcutaneous use: US prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761399s000lbl.pdf. Accessed 29 Oct 2025."},{"key":"1505_CR3","unstructured":"European Medicines Agency. Omlyclo (international non-proprietary name: omalizumab): EU assessment report. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/omlyclo-epar-public-assessment-report_en.pdf. Accessed 29 Oct 2025."},{"issue":"11","key":"1505_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/clt2.12204","volume":"12","author":"M Maurer","year":"2022","unstructured":"Maurer M, Saini SS, McLendon K, et al. Pharmacokinetic equivalence of CT-P39 and reference omalizumab in healthy individuals: a randomised, double-blind, parallel-group, phase 1 trial. Clin Transl Allergy. 2022;12(11):1\u20139.","journal-title":"Clin Transl Allergy."},{"issue":"8","key":"1505_CR5","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1111\/all.16446","volume":"80","author":"S Saini","year":"2025","unstructured":"Saini S, Maurer M, Dytyatkovska Y, et al. CT-P39 compared with reference omalizumab in chronic spontaneous urticaria: results from a double-blind, randomized, active-controlled, phase 3 study. Allergy. 2025;80(8):2167\u201377.","journal-title":"Allergy"},{"issue":"2","key":"1505_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/1750743X.2025.2467026","volume":"17","author":"T Hasunuma","year":"2025","unstructured":"Hasunuma T, Grattan C, Eto T, et al. Pharmacokinetics and safety of CT-P39 via auto-injector are comparable to reference omalizumab via pre-filled syringe. Immunotherapy. 2025;17(2):113\u201321.","journal-title":"Immunotherapy"},{"issue":"6","key":"1505_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.70069","volume":"15","author":"C Grattan","year":"2025","unstructured":"Grattan C, Dytyatkovska Y, Springer M, et al. Efficacy and safety of CT-P39, an omalizumab biosimilar, in chronic spontaneous urticaria: 16-week follow-up study. Clin Transl Allergy. 2025;15(6):e70069.","journal-title":"Clin Transl Allergy"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01505-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01505-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01505-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:37:21Z","timestamp":1768833441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01505-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1505"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01505-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process, the manufacturer of the agent under review, Celltrion Inc., was offered an opportunity to comment on this article. Changes resulting from the comments received from Aram Kang, PharmD and Dong-Hyeon Kim, DVM, PhD, were made on the basis of scientific completeness and accuracy. Michael B. Brown is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}